US 2011/0236375 A1 · ANTIBODY VARIANTS WITH ENHANCED COMPLEMENT ACTIVITY

Abstract

The present invention relates to novel Fc variants that comprise at least one novel amino acid residue which may provide for enhanced effector function. More specifically, this invention provides Fc variants that have modified binding affinity to one or more Fc receptor or ligand (e.g., Fc gamma R, C1q). Additionally, the Fc variants have altered complement dependent cytotoxicity (CDC) activity and/or antibody-dependent cell-mediated cytotoxicity (ADCC). The invention further provides methods and protocols for the application of said Fc variants, particularly for therapeutic purposes.

Claims17

Dependent claims

A protein comprising a variant Fc region, wherein said variant Fc region comprises two substitutions as compared to a parent wild-type Fc region, wherein said variant Fc region exhibits greater complement dependent cytotoxicity as comared to said parent wild-type Fc region;

wherein said substitutions are selected from the group consisting of 267E, 268F, and 324T, wherein the numbering is according to the EU index.

Dependencies are inferred from the claim text.

Facts

Application

13/009,820Filed 19 Jan 2011

Priority

19 Jan 2010

Published

29 Sep 2011

Term ends

Not estimatedThe source records don’t support an estimate.

Classification10 codes

C07K 16/2887
Against receptors, cell surface antigens or cell surface determinants: against CD20
C07K 16/2803
Against receptors, cell surface antigens or cell surface determinants: against the immunoglobulin superfamily
C07K 16/2878
Against receptors, cell surface antigens or cell surface determinants: against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
C07K 2317/52
Characterized by immunoglobulin fragments: constant or Fc region; Isotype

Antibody variants with enhanced complement activity

Life of this patent

Antibody variants with enhanced complement activity

Life of this patent

Abstract

Claims17